Patents by Inventor Hun-Chi Lin

Hun-Chi Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Extracorporeal pathogen reduction system
    Patent number: 7470245
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal blood system.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: December 30, 2008
    Assignee: XEPMED, Inc.
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Extracorporeal pathogen reduction system
    Patent number: 7314460
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: January 1, 2008
    Assignee: XEP MED, Inc.
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Extracorporeal pathogen reduction system
    Publication number: 20050274672
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal blood system.
    Type: Application
    Filed: June 22, 2005
    Publication date: December 15, 2005
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Extracorporeal pathogen reduction system
    Patent number: 6969367
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 29, 2005
    Assignee: XEPMED, Inc.
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Extracorporeal pathogen reduction system
    Publication number: 20050242033
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.
    Type: Application
    Filed: July 6, 2005
    Publication date: November 3, 2005
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Extracorporeal pathogen reduction system
    Publication number: 20050059921
    Abstract: The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.
    Type: Application
    Filed: November 24, 2003
    Publication date: March 17, 2005
    Inventors: Hosheng Tu, Hun-Chi Lin, Yu-An Chang
  • Recombinant 68,000 dalton collagenase of Clostridium histolyticum
    Patent number: 5418157
    Abstract: Genetically engineered E. coli carry vectors containing inserts that code for Clostridium histolyticum collagenase. These inserts code for: (a) a form of collagenase having a molecular weight of about 68,000 daltons in the essential absence of larger forms of collagenase; (b) the 68 kd form of collagenase and a fusion polypeptide consisting of the collagenase protein fused to at least a portion of the .beta.-galactosidase protein of E. coli or (3) the 68 kd form of collagenase and polypeptides of molecular weight of from above about 68,000 daltons to about 100,000 daltons and having the enzymatic activity of C. histolyticum collagenase as indicated by digestion of .sup.3 H-acetylated collagen and by specific inhibition by 1,10-phenanthroline plus EDTA. The collagenase genes in the transformed E. coli are expressed efficiently in the transformed cells to yield enzymatically active and immunologically cross-reactive collagenase.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: May 23, 1995
    Inventors: Hun-Chi Lin, Shau-Ping Lei
  • Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum
    Patent number: 5177017
    Abstract: Genetically engineered E. coli carry vectors containing inserts that code for Clostridium histolyticum collagenase. These inserts code for: (a) a form of collagenase having a molecular weight of about 68,000 daltons in the essential absence of larger forms of collagenase; (b) the 68 kd form of collagenase and a fusion polypeptide consisting of the collagenase protein fused to at least a portion of the .beta.-galactosidase protein of E. coli; or (3) the 68 kd form of collagenase and polypeptides of molecular weight of from above about 68,000 daltons to about 100,000 daltons and having the enzymatic activity of C. histolyticum collagenase as indicated by digestion of .sup.3 H-acetylated collagen and by specific inhibition by 1,10-phenanthroline plus EDTA. The collagenase genes in the transformed E. coli are expressed efficiently in the transformed cells to yield enzymatically active and immunologically cross-reactive collagenase.
    Type: Grant
    Filed: March 22, 1990
    Date of Patent: January 5, 1993
    Assignee: Trigen, Inc.
    Inventors: Hun-Chi Lin, Shau-Ping Lei